Brussels (Belgium), 22 December 2010, 7.00 AM — UCB announced today that the company has initiated a project to build in-house biotech microbial manufacturing capacity in Bulle, Switzerland to secure demand for its core product Cimzia® (certoluzimab pegol).
The new manufacturing unit should be operational in 2015 and requires an investment of €250m in two steps.
“We want to be able to meet our projected future demand for 2015 and beyond for Cimzia® – by adding internal capacity to our existing capacities with our productions partners,” says Michele Antonelli, Executive Vice President UCB and responsible for Technical Operations, Quality Assurance and HSE.
“Our site in Bulle is the right place and most cost effective location to build our own biotech manufacturing unit which enables us to further improve our productivity at attractive terms. The new unit together with the bio-pilot-plant under construction in Braine l’Alleud, Belgium will also strengthen our ability to deliver our future biological products.”